Abstract Title:

First Report of Antimicrobial Efficacy of Novel Ocular Anti-Infective/Anti-Inflammatory CLSA_1506 : In vitro Activity Against Common Bacterial, Fungal and Viral Pathogens

Presentation Start/End Time:

Wednesday, May 09, 2007, 11:15 AM - 1:00 PM


Hall B/C

Reviewing Code:

116 antibiotics - CO

Author Block:

B.Liang1, K.-T.Lin2. 1CLS Pharmaceuticals, Inc., New York, NY; 2Mycometrics, LLC., Monmouth Junction, NJ.


472 conjunctivitis,421 antibiotics/antifungals/antiparasitics,424 antiviral drugs

Purpose: To describe the in vitro efficacy of novel ocular anti-infective / anti-inflammatory agent CLSA_1506 against several common ocular pathogens including bacteria and fungi.
Methods: One volume of a 2.2% (w/w) solution of CLSA_1506 was added in trypticase soy broth mixtures with ocular isolates of Pseudomonas aeuroginosa, Proteus mirabilis, Serratia maracescens, Staphylococcous aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Methicilin Resistant Staphylococcus Aureus and Klebsiella pneumoniae and in malt extract broth mixtures with ocular isolates of Candida parapsilosis, Candida albicans and Apergillus niger. After the treatment of pathogens with the analyte (drug), a 100 microliter innoculum was immediately removed and plated onto standard culture media at indicated inoculation times of 0 (immediately after the treatment), 24 and 72 hours. Plates were monitored for microbial growth and colony counts obtained at 24 hours for bacteria and 3 days for yeasts and 5 days for fungi.
For HdaV-4 assay, a 0.5 mL aliquot of 2.2% (w/w) solution of CLSA_1506 was combined with 0.5 mL of virus stock in a sterile tube. The tubes were then incubated at 37°C for 30 minutes. Hank’s Balanced Salt Solution (HBSS) was used as the negative control. Infectivity of A549 cells was determined. Immediately following incubation the test and control articles were titrated for infectious HAdV-4.
Results: For all species tested, no growth of any microbial colonies was noted for any species after incubation periods for 0, 24 or 72 hours. A control group (with no analyte treatment) was observed for growth of all species tested. HAdV-4 was completely inactivated by CLSA-1506.
Conclusions: CLSA_1506 eliminates many common ocular pathogens on contact and may be a useful ocular antibiotic in suspected bacterial, fungal or mixed infections.

Commercial Relationship:

  B. Liang, CLS Pharmaceuticals, Inc., F; K. Lin, Mycometrics, LLC, F.


CLS Pharmaceuticals